CNBC reports (video) an unusually high volume of call options in Pharmasset (VRUS +84.7%) were...
CNBC reports (video) an unusually high volume of call options in Pharmasset (VRUS +84.7%) were purchased just a few days before the buyout of the company by Gilead Sciences (GILD -9.7%). Analysts say the activity may get more than a passing glance look from regulators.
From other sites
Video at CNBC.com (Aug 24, 2015)
Video at CNBC.com (Jul 29, 2015)
at CNBC.com (May 22, 2015)
Video at CNBC.com (Feb 3, 2015)
at CNBC.com (Feb 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs